ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2008
Anaphylaxis following quadrivalent human papillomavirus vaccination.
Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 126 citations in OpenAlex.
- Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study.Human vaccines & immunotherapeutics · 2022Article
- Allergo Journal : interdisziplinare Zeitschrift fur Allergologie und Umweltmedizin : Organ der Deutschen Gesellschaft fur Allergie- und Immunitatsforschung · 2022Review
- Anaphylaxis to additives in vaccines.Allergo journal international · 2022Review
- Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives.Allergy · 2021Review
- Human papillomavirus vaccine for children and adolescents.Paediatrics & child health · 2018Review
- Vaccine-associated hypersensitivity.The Journal of allergy and clinical immunology · 2018Review
- Risk of anaphylaxis after vaccination in children and adults.The Journal of allergy and clinical immunology · 2016Article
- Human papillomavirus vaccination for boys.Canadian family physician Medecin de famille canadien · 2015Article
- HPV vaccine for cancer and wart prevention.Canadian family physician Medecin de famille canadien · 2015Article
- Review
- Vaccination against HPV-Associated Neoplasias: Recommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society - AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018.Geburtshilfe und Frauenheilkunde · 2014Article
- Human papilloma virus vaccination programs reduce health inequity in most scenarios: a simulation study.BMC public health · 2012Article
- Update on Human Papillomavirus (HPV) Vaccines: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)Canada communicable disease report = Releve des maladies transmissibles au Canada · 2012Article
- Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer.Current opinion in virology · 2011Review
- Evidence-based clinical guidelines for immigrants and refugees.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2011Article
- [Adverse effects of the human papillomavirus vaccine].Atencion primaria · 2011Article
- Review
- Review of Gardasil.Journal of vaccines & vaccination · 2010Article
- Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine.International journal of women's health · 2010Article
- Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2007, Australia implemented the National human papillomavirus (HPV) Vaccination Program, which provides quadrivalent HPV vaccine free to all women aged 12-26 years. Following notification of 7 presumptive cases of anaphylaxis in the state of New South Wales, Australia, we verified cases and compared the incidence of anaphylaxis following HPV vaccination to other vaccines in comparable settings.
methodsWe contacted all patients with suspected anaphylaxis and obtained detailed histories from telephone interviews and a review of medical records. A multidisciplinary team determined whether each suspected case met the standardized Brighton definition. Some participants also received skin-prick allergy testing for common antigens and components of the HPV vaccine.
resultsOf 12 suspected cases, 8 were classified as anaphylaxis. Of these, 4 participants had negative skin-prick test results for intradermal Gardasil. From the 269 680 HPV vaccine doses administered in schools, 7 cases of anaphylaxis were identified, which represents an incidence rate of 2.6 per 100 000 doses (95% CI 1.0-5.3 per 100 000). In comparison, the rate of identified anaphylaxis was 0.1 per 100 000 doses (95% CI 0.003-0.7) for conjugated meningococcal C vaccination in a 2003 school-based program.
interpretationBased on the number of confirmed cases, the estimated rate of anaphylaxis following quadrivalent HPV vaccine was significantly higher than identified in comparable school-based delivery of other vaccines. However, overall rates were very low and managed appropriately with no serious sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.